You are here

Remicade

Can Johnson & Johnson Replace Remicade for $100 Million Upfront?

Can Johnson & Johnson Replace Remicade for $100 Million Upfront?

Motley Fool

inflammatory bowel disease

Flag link:

Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst

Remicade biosims from Pfizer, Merck unlikely to turn the tide in 2018: analyst

Fierce Pharma

Flag link:

Biosimilars Council Sides with Pfizer in Antitrust Dispute with J&J

Biosimilars Council Sides with Pfizer in Antitrust Dispute with J&J

JD Supra

Flag link:

J&J’s move to cut Remicade price cost some big bucks, but guarded against Pfizer’s copycat

J&J’s move to cut Remicade price cost some big bucks, but guarded against Pfizer’s copycat

Endpoints

Flag link:

The 2018 biosimilar litigation landscape: A primer

The 2018 biosimilar litigation landscape: A primer

BioPharma Dive

Flag link:

Pfizer Not Planning US Launch of its Second Remicade Biosimilar Approved by FDA

Pfizer Not Planning US Launch of its Second Remicade Biosimilar Approved by FDA

RAPS.org

Flag link:

Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval

Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval

Yahoo/Reuters

rheumatoid arthritis

Crohn's Disease

Flag link:

[forum discussion]Pfizer Jumps the Shark over Biosimilar Failure

[forum discussion]Pfizer Jumps the Shark over Biosimilar Failure

Cafepharma Message Boards

Flag link:

Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilar

Pfizer Accuses J&J of Anticompetitive Business Practices over Remicade Biosimilar

JD Supra

anticompetitive practices

Flag link:

As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report

As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: report

Fierce Pharma

Flag link:

Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy

Janssen drops U.S. lawsuit against Samsung Bioepis' Remicade copy

Yahoo/Reuters

Samsung Bioepis

rheumatoid arthritis

Flag link:

Pfizer ready for a fight as biosimilar sales continue to lag

Pfizer ready for a fight as biosimilar sales continue to lag

BioPharma Dive

Flag link:

J&J's Remicade stands firm against biosim competition in Q3

J&J's Remicade stands firm against biosim competition in Q3

Fierce Pharma

Flag link:

[video+transcript]Is This How Drugmakers Will Kill Biosimilars?

[video+transcript]Is This How Drugmakers Will Kill Biosimilars?

Motley Fool

Flag link:

Pfizer is falling short in a competitive market, Johnson & Johnson says as it hits back at Remicade biosimilar suit

Pfizer is falling short in a competitive market, Johnson & Johnson says as it hits back at Remicade biosimilar suit

Fierce Pharma

Flag link:

This squabble between two big drugmakers could have major implications for the U.S. health care system

This squabble between two big drugmakers could have major implications for the U.S. health care system

Marketwatch

Flag link:

Pfizer files US lawsuit against Johnson & Johnson over "anticompetitive" practices related to Remicade biosimilar

Pfizer files US lawsuit against Johnson & Johnson over "anticompetitive" practices related to Remicade biosimilar

First Word Pharma

Flag link:

Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars

Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars

Drug Channels

Flag link:

10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright

10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright

Motley Fool

consumer health

Flag link:

FDA Form 483 for Celltrion May Offer a Glimpse Into Limited Uptake for Remicade Biosimilar

FDA Form 483 for Celltrion May Offer a Glimpse Into Limited Uptake for Remicade Biosimilar

RAPS.org

Flag link:

Pages